A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

NCT07152405 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

490

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: BL-M07D1
DRUG: Investigator's choice of chemotherapy

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]